Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.

Cancer medicine - 1 Jan 2020

McDuff Susan G R, Dietrich Jorg, Atkins Katelyn M, Oh Kevin S, Loeffler Jay S, Shih Helen A

Abstract excerpt

PURPOSE: The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy. This article aims to evaluate the evidence and rationale for the widespread use of TMZ instead of PCV for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 1
Share to Chromosomes, Human, Pair 19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Progression-Free Survival

Share to Randomized Controlled Trials as Topic

Share to Temozolomide

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 31701682
DOI: 10.1002/cam4.2686
PMCID: PMC6943166

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.PMID 31701682Read ↗

Current management of low-grade gliomas.Semantic proximity Read ↗

Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas.Semantic proximity Read ↗

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.Semantic proximity Read ↗

Low-grade glioma.Semantic proximity Read ↗

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.Semantic proximity Read ↗

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.Semantic proximity Read ↗

Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.Semantic proximity Read ↗

Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.Semantic proximity Read ↗

Low-grade gliomas.Semantic proximity Read ↗

Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.Semantic proximity Read ↗

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.Semantic proximity Read ↗

Could upfront temozolomide chemotherapy postpone the intervene of radiotherapy in young patients with high-risk low-grade gliomas?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.